Moderna (@moderna

Moderna

2,905 posts

Moderna

@moderna_tx

Our mission is to deliver the greatest possible impact to people through mRNA medicines.

Cambridge, MA

Joined December 2013

Moderna
@moderna_tx
Jan 25, 2021
We just announced that the Moderna COVID-19 Vaccine retains neutralizing activity against emerging variants first identified in the U.K. and the Republic of South Africa. Read more: buff.ly/39i2cOp
Moderna
@moderna_tx
Jan 27, 2022
ANNOUNCEMENT 📢: We are proud to announce that the first participant has been dosed in the Phase 1 study of mRNA-1644, our experimental #HIV #mRNA #vaccine candidate. Learn more about this exciting venture with @IAVI: investors.modernatx.com/news/news-deta…
Moderna
@moderna_tx
Sep 9, 2021
Today, we shared positive pre-clinical data demonstrating our ability to combine 6 mRNAs against 3 different respiratory viruses in 1 vaccine: COVID-19 booster + Flu booster + RSV booster. #mRNA
Moderna
@moderna_tx
Nov 16, 2020
We just announced that mRNA-1273, our COVID-19 vaccine candidate, has met its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study. Read more: buff.ly/3puVGK6
Moderna
@moderna_tx
Nov 30, 2020
We just announced the primary efficacy analysis in the Phase 3 COVE study for mRNA-1273, our COVID-19 vaccine candidate and that today, we plan to request an Emergency Use Authorization from the U.S. FDA & conditional approval from the EMA. Read more: buff.ly/2Jt56Fz
Moderna
@moderna_tx
Mar 22, 2021
We just announced that the Philippines has secured 7 million additional doses of our COVID-19 vaccine through a new supply agreement & partnership with the private sector, bringing its confirmed order commitment to 20 million doses. Read more: buff.ly/3f4hzgs
Moderna
@moderna_tx
May 6, 2024
Your risk of #LongCOVID rises with each additional infection. A recent study has shown that by their third COVID infection, patients have a 40% chance of developing Long COVID symptoms. Learn more about the threat of Long COVID: modernatx.com/en-US/media-ce…
Moderna
@moderna_tx
Mar 16, 2021
We just announced that the first participants have been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, our vaccine candidate against COVID-19, in children ages 6 months to less than 12 years. Read more: investors.modernatx.com/news-releases/…
Moderna
@moderna_tx
May 18, 2020
Summary of our SARS-CoV-2 #vaccine (mRNA-1273) interim Phase 1 data. Read more: buff.ly/3bEUhZ9 #mRNA
Moderna
@moderna_tx
Jul 14, 2020
We just announced interim results from the NIH-led Phase 1 Study of our #mRNA #vaccine against COVID-19 (mRNA-1273) in @NEJM. Read more: buff.ly/2WjGoLr
Moderna
@moderna_tx
Nov 26, 2021
We just announced our strategy to address the omicron (B.1.1.529) SARS-CoV-2 variant. Read more: investors.modernatx.com/news-releases/…
Moderna
@moderna_tx
Nov 16, 2020
We just announced a longer shelf life at refrigerated temperatures for mRNA-1273, our COVID-19 vaccine candidate. Read more: buff.ly/3f2RE6V
Moderna
@moderna_tx
Nov 30, 2020
Update: Moderna’s data for the Emergency Use Authorization request for mRNA-1273 has been submitted to the U.S. FDA.
Moderna
@moderna_tx
Feb 9, 2021
We just announced two supply agreements for the COVID-19 Vaccine Moderna: one with the government of Taiwan for 5 million doses and another with the government of Colombia for 10 million doses. Read more: buff.ly/3p9RRZo